Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabio Angeli

Showing results (81-90 of 313) with videos related to

Pageof 32
Sort By:
Journal of Hypertension|June 30, 2021
SARS-CoV-2 infection and ACE2 inhibitionFabio Angeli, Gianpaolo Reboldi, Paolo Verdecchia
Journal of Hypertension|March 6, 2020
Blood pressure variability and risk of stroke in chronic kidney diseaseFabio Angeli, Gianpaolo Reboldi, Paolo Verdecchia
Clinical Chemistry and Laboratory Medicine|June 12, 2021
Ageing, ACE2 deficiency and bad outcome in COVID-19Fabio Angeli, Gianpaolo Reboldi, Paolo Verdecchia
European Journal of Internal Medicine|April 2, 2023
Severe acute respiratory syndrome coronavirus 2 evolution: How mutations affect XBB.1.5 variantMartina Zappa, Paolo Verdecchia, Fabio Angeli
Hypertension (Dallas, Tex. : 1979)|August 8, 2007
New-onset diabetes, antihypertensive treatment, and outcomePaolo Verdecchia, Fabio Angeli, Gianpaolo Reboldi
The New England Journal of Medicine|October 27, 2020
RAAS Inhibitors and Risk of Covid-19Fabio Angeli, Paolo Verdecchia, Gianpaolo Reboldi
Journal of the American Society of Hypertension : JASH|October 28, 2015
The SPRINT trialPaolo Verdecchia, Fabio Angeli, Gianpaolo Reboldi
Hypertension (Dallas, Tex. : 1979)|October 14, 2015
Cardiac Benefits of an Intensive Blood Pressure Control in Diabetes MellitusPaolo Verdecchia, Fabio Angeli, Gianpaolo Reboldi
Journal of Hypertension|June 30, 2016
Home blood pressure and treatment decisions: caveat emptorFabio Angeli, Gianpaolo Reboldi, Paolo Verdecchia
Heart Asia|June 22, 2016
The 2014 hypertension guidelines: implications for patients and practitioners in AsiaFabio Angeli, Gianpaolo Reboldi, Paolo Verdecchia
Pageof 32

Showing results (81-90 of 313) with videos related to

Sort By:
Pageof 32
Journal of Hypertension|June 30, 2021
SARS-CoV-2 infection and ACE2 inhibitionFabio Angeli, Gianpaolo Reboldi, Paolo Verdecchia
Journal of Hypertension|March 6, 2020
Blood pressure variability and risk of stroke in chronic kidney diseaseFabio Angeli, Gianpaolo Reboldi, Paolo Verdecchia
Clinical Chemistry and Laboratory Medicine|June 12, 2021
Ageing, ACE2 deficiency and bad outcome in COVID-19Fabio Angeli, Gianpaolo Reboldi, Paolo Verdecchia
European Journal of Internal Medicine|April 2, 2023
Severe acute respiratory syndrome coronavirus 2 evolution: How mutations affect XBB.1.5 variantMartina Zappa, Paolo Verdecchia, Fabio Angeli
Hypertension (Dallas, Tex. : 1979)|August 8, 2007
New-onset diabetes, antihypertensive treatment, and outcomePaolo Verdecchia, Fabio Angeli, Gianpaolo Reboldi
The New England Journal of Medicine|October 27, 2020
RAAS Inhibitors and Risk of Covid-19Fabio Angeli, Paolo Verdecchia, Gianpaolo Reboldi
Journal of the American Society of Hypertension : JASH|October 28, 2015
The SPRINT trialPaolo Verdecchia, Fabio Angeli, Gianpaolo Reboldi
Hypertension (Dallas, Tex. : 1979)|October 14, 2015
Cardiac Benefits of an Intensive Blood Pressure Control in Diabetes MellitusPaolo Verdecchia, Fabio Angeli, Gianpaolo Reboldi
Journal of Hypertension|June 30, 2016
Home blood pressure and treatment decisions: caveat emptorFabio Angeli, Gianpaolo Reboldi, Paolo Verdecchia
Heart Asia|June 22, 2016
The 2014 hypertension guidelines: implications for patients and practitioners in AsiaFabio Angeli, Gianpaolo Reboldi, Paolo Verdecchia
Pageof 32